Smith & Nephew plc
HealthcareNYSE:SNN · New York Stock Exchange
-$0.10 today
Vol 0.65M · Avg 1.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
11.8%
avg 10.8%
ROIC
9.0%
avg 7.4%
ROA
6.0%
avg 5.9%
Analysis
ROE is currently the strongest return metric at 11.8% versus its period average of 10.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Deepak S. Nath | Chief Executive Officer & Director | $4.61M | — | 54 | — | — |
John Terence Rogers | Chief Financial Officer & Executive Director | $2.81M | — | 57 | — | — |
Ajay Dhankhar | Chief Corporate Development & Strategy Officer | — | — | 55 | — | — |
Vasant Padmanabhan | President Research & Development, ENT and Emerging Markets | — | — | 59 | — | — |
Emily Heaven | Head of Investor Relations | — | — | — | — | — |
Paul Connolly | President of Global Operations | — | — | 58 | — | — |
Alison Parkes | Chief Compliance Officer & Compliance APAC | — | — | 54 | — | — |
Elga Lohler | Chief Human Resources Officer | — | — | 58 | — | — |
Helen Barraclough | Group General Counsel & Company Secretary | — | — | 47 | — | — |
Charles Reynolds | Head of Corporate Communication | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -17.2% | +8.6% (15yr)1 analysts |
| Revenue | N/A | N/A | +3.9% | +4.0% (15yr)4 analysts |
| Net Income | N/A | N/A | -17.5% | +8.5% (15yr)4 analysts |
| EBIT | N/A | N/A | -9.5% | +2.5% (15yr)4 analysts |
Analysis
Recent growth has been strongest in Revenue at +3.9% over three years. Forward estimates point to EPS at +8.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Centene Corporation
NYSE:CNC
$32.19B
Royalty Pharma plc
NASDAQ:RPRX
$23.60B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B
Hologic, Inc.
HOLX
$16.97B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$16.06B
Tenet Healthcare Corporation
NYSE:THC
$15.04B
Medpace Holdings, Inc.
NASDAQ:MEDP
$13.35B
The Cooper Companies, Inc.
NASDAQ:COO
$13.24B
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
$12.36B
Tempus AI, Inc.
NASDAQ:TEM
$8.35B
Who manages SNN?
Smith & Nephew plc (SNN) lists 10 active executives. The top listed executive is Ajay Dhankhar, Chief Corporate Development & Strategy Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.